COMPANY PROFILE

Dizal Pharmaceutical

Global, science-oriented pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines

Pudong, ChinaFounded 2017Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2026

Revenue $100–500M Latest reported FY

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Dizal Pharmaceutical

Dizal Pharmaceutical is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for the treatment of cancer and immunological diseases. The company's pipeline includes sunvozertinib, an EGFR inhibitor for non-small cell lung cancer, which has received FDA approval.

Dizal's business model revolves around in-house research and development, clinical trials, and seeking regulatory approval for its drug candidates. The company generates revenue through the sale of its approved drugs. The primary clients are patients suffering from specific types of cancer and immunological conditions, and the company operates in the global pharmaceutical market.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Pudong, China
Employees: 113
Open positions: 8
Dealroom signal: 71.5/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPO✓Exit	Nov 2021	$0	—	Undisclosed	—
EARLY VC✓Equity / VC	Aug 2020	$100M	$400M	Lilly Asia Ventures · HSG	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Dizal Pharmaceutical website traffic

Latest recorded traffic for Dizal Pharmaceutical is 9K monthly website visits, up 500% over the last three months. Dizal Pharmaceutical's team grew 2.7% over the past year.

Latest monthly visits9K 3-month web change+500% 1-year team growth+2.7%

Monthly website visitsAug 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

-Wuxi, China, Eastern Asia, Asia · Sales · Jul 30, 2026 Clinical Research Manager 2026-07-17Zhangjiang, Pudong, Shanghai, 201203, China · Other · Jul 30, 2026 -Zhangjiang, Pudong, Shanghai, 201203, China · Sales · Jul 16, 2026 CMC Regulatory Affairs (Sr.) Manager 2026-06-08Zhangjiang, Pudong, Shanghai, 201203, China · Other · Jun 11, 2026

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VOVodorasloYour solution to better air quality	Sofia, Bulgaria	Operational	1	$61K	$132K
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational
TBTome BiosciencesTome Biosciences is the programmable gene insertion company	Watertown, United States	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
VSVuja De SciencesDeveloper of anti-metastasis therapy for rare cancers	Natick, United States	Operational